ArticleLancet regional health. Americas2026
Tuberculosis infection tests for contact screening in Brazil: a cost-effectiveness analysis.
Article in Lancet regional health. Americas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The World Health Organization has recommended three new tuberculosis (TB) antigen-based skin tests (TBST) (Diaskintest®, C-TST®, Cy-TB®) for the diagnosis of tuberculosis infection (TBI). Household contacts (HHC) of people with pulmonary TB are at increased risk for TBI. We evaluated the cost-effectiveness of the use of TBST and of QuantiFERON-TB Plus® (QFT-Plus®) compared to the tuberculin skin test (TST) in Brazil. Methods: A state-transition Markov model simulating four distinct hypothetical cohorts of 10,000 HIV-negative contacts of different ages (3 months-4 years, 5-9 years, 10-14 years, and 15 or older) was built over five annual cycles for TBI testing and tuberculosis preventive treatment (TPT) under the Brazilian public health system perspective. Effectiveness was estimated from systematic reviews and costs were raised from the Brazilian government (TST and QFT-Plus®) and from the manufacturers (TBST). Incremental cost-effectiveness per TB case averted was calculated. Findings: TBST has similar accuracy to QFT-Plus®, and all are more specific than TST. TBST are less costly compared with TST or QFT-Plus®. All TBST were cost-saving regardless of the age group compared to TST or QFT-Plus®. Cy-Tb® was the most cost-saving, followed by Diaskintest® and C-TST®. Interpretation: The incorporation of the new TBST for screening in the Brazilian public health system would be a cost-saving alternative for contacts. Because these tests require the same infrastructure and human resources skills as TST, the tests could be readily implemented. Funding: CNPq and Stop TB Partnership.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.